



Docket No.: 04279/100M213-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Christopher P. Holmes et al.

Application No.: 10/555,860

Confirmation No.: 4443

Filed: November 1, 2005

Art Unit: 1654

For: NOVEL SPACER MOIETY FOR POLY  
(ETHYLENE GLYCOL) MODIFIED PEPTIDE  
BASED COMPOUNDS

Examiner: J. R. Kosack

**AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action mailed by the United States Patent and Trademark Office (the "PTO") on October 28, 2009 in connection with this application and pursuant to Rule 111 of the Rules of Practice, please enter the following amendments and consider the accompanying Remarks. The following papers are also provide as part of this Amendment, attached hereto at Appendices A-C as follows:

Appendix A: A substitute specification pursuant to 37 C.F.R. 1.125(b) and (c), with markings to indicate changes relative to the immediate prior version of the specification of record;

Appendix B: A clean copy of the amended specification; and

Appendix C: New sheets presenting new drawing Figures 1-16.

In addition, Applicants are also submitting the following documents with this  
Response:

- (1) A Petition for Extension of Time, requesting that the time period for responding to the Office Action be extended for a period of **one** (1) month, from January 28, 2010 up to and including **Monday, March 1, 2010**;
- (2) Terminal Disclaimers over each of U.S. Patent Nos. 7,084,245 (“the ‘245 patent”); 7,414,105 (“the ‘105 patent”) and 7,528,104 (“the ‘104 patent”);
- (3) a Supplemental Information Disclosure Statement (“IDS”), including Form PTO/SB/08a and copies of the publication cited therein (Dubowchik *et al.*, *Bioorganic & Medicinal Chemistry Letters* (2002) 12:1529-1532); and
- (4) a Fee Transmittal letter (Form PTO/SB/17) accompanied by payment of the estimated Extension, Terminal Disclaimer and IDS fees.

It is believed that no additional fees are required for these submissions. However, should the PTO determine that any additional fee is required or that any refund is due for this application, then Applicants hereby authorize and request that the Commissioner charge the required fee(s) (including any required Extension fee(s)) and/or credit the refund(s) due to Deposit Account No. 04-0100 of Applicants’ undersigned representatives.

**Amendments to the Specification** begin on page 4 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 5 of this paper.

**Amendments to the Drawings** begin on page 13 of this paper and include both an attached replacement sheet and an annotated sheet showing changes.

**Remarks/Arguments** begin on page 14 of this paper.

**Appendices** including marked-up and clean copies of the substitute specification and new drawing figures are attached following page 18 of this paper.

\* \* \* \* \*